Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- HAVEN 2
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN2)
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
Hemophilia Hemophilia A
- Results
-
Download -
Study results
LPS_BH29992_HAVEN 2_final results_Mar2021_African_South Africa
(PDF, 1.2 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_French_France
(PDF, 1.3 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_German
(PDF, 0.6 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_Japanese
(PDF, 2.3 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_Sotho_South Africa
(PDF, 1.2 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_Spanish_LATAM
(PDF, 0.7 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_Spanish_Spain
(PDF, 0.7 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_Turkish
(PDF, 1.1 MB)
LPS_BH29992_HAVEN 2_final results_Mar2021_Zulu_South Africa
(PDF, 1.2 MB)
LPS BH29992 HAVEN 2 Final Results March 2023 English
(PDF, 1.3 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com